InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Oramed (ORMP) stock is falling hard Thursday after announcing a Phase 3 clinical trial of its diabetes treatment missed its primary endpoint.
The post Why Is Oramed (ORMP) Stock Down 75% Today? appeared first on InvestorPlace.
More From InvestorPlace